Affimed NV logo

Affimed NVNASDAQ: AFMD

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Germany

IPO:

12 September 2014

Next earnings report:

14 November 2024

Last dividends:

N/A

Next dividends:

N/A
$51.12 M
-93%vs. 3y high
35%vs. sector
-vs. 3y high
-vs. sector
-69%vs. 3y high
52%vs. sector
-42%vs. 3y high
83%vs. sector

Price

regular market | Fri, 01 Nov 2024 13:30:00 GMT
$3.26+$0.03(+0.93%)

Dividend

No data over the past 3 years
$165.80 K$2.18 M
$165.80 K-$16.64 M

Analysts recommendations

Institutional Ownership

AFMD Latest News

Affimed N.V. (AFMD) Q2 2024 Earnings Call Transcript
seekingalpha.com05 September 2024 Sentiment: NEUTRAL

Affimed N.V. (NASDAQ:AFMD ) Q2 2024 Earnings Conference Call September 5, 2024 8:30 AM ET Company Participants Alex Fudukidis - Head, Investor Relations Shawn Leland - Chief Executive Officer Andreas Harstrick - Chief Medical Officer Michael Wolf - Vice President, Finance Conference Call Participants Maury Raycroft - Jefferies Daina Graybosch - Leerink Partners Bill Jahangiri - Truist Securities Li Watsek - Cantor Brad Canino - Stifel Swayampakula Ramakanth - H.C.

Affimed Follow Up: Upcoming Acimtamig And AFM24 Updates Could Be Positive Catalysts
seekingalpha.com04 September 2024 Sentiment: POSITIVE

On 06/11/24, I published an article on Affimed focused on my belief the company's upcoming acimtamig update would be positive. It was, and Affimed's stock popped the next day. The stock has since dropped to below $4/s based, in my opinion, on investor's perceptions that a dilutive capital raise is coming soon. AFMD's 2Q '24 Earnings Call is scheduled for tomorrow, 09/05/24. And we are due for an acimtamig and AFM24 3Q '24 update before the end of the month.

Affimed Appoints New CEO, Shares Fall on Leadership Change
zacks.com04 September 2024 Sentiment: NEUTRAL

AFMD appoints Shawn M. Leland as the company's new chief executive officer.

Affimed Appoints Shawn M. Leland as Chief Executive Officer
globenewswire.com03 September 2024 Sentiment: POSITIVE

MANNHEIM, Germany, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that Shawn M. Leland, PharmD, RPh has been appointed as Chief Executive Officer (CEO). Dr. Andreas Harstrick, who has been serving as acting CEO since January 2024 will continue in his position as Chief Medical Officer (CMO).

Affimed to Report Second Quarter 2024 Financial Results & Corporate Update on September 5, 2024
globenewswire.com29 August 2024 Sentiment: POSITIVE

MANNHEIM, Germany, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release second quarter 2024 results and corporate update on Thursday, September 5, 2024. The Company will host a conference call at 8:30 a.m. EDT / 14:30 CET.

Affimed to Report First Quarter 2024 Financial Results & Corporate Update on June 12, 2024
globenewswire.com05 June 2024 Sentiment: POSITIVE

MANNHEIM, Germany, June 05, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release first quarter 2024 results and corporate update on Wednesday, June 12, 2024. The Company will host a conference call at 8:30 a.m. EDT / 14:30 CET.

Affimed (AFMD) Soars on Upbeat Follow-Up Data From NSCLC Study
zacks.com04 June 2024 Sentiment: POSITIVE

Affimed (AFMD) rallies 69% on positive follow-up efficacy data from its early to mid-stage study of the AFM24/Tecentriq combo therapy to treat heavily-pretreated EGFR wild-type NSCLC patients.

7 Penny Biotech Stocks to Triple Your Investment
investorplace.com28 May 2024 Sentiment: POSITIVE

One of the oldest maxims in investing is that higher risk produces greater returns. That maxim holds particularly true across penny biotech stocks.

Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024
globenewswire.com23 May 2024 Sentiment: POSITIVE

MANNHEIM, Germany, May 23, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that an update from the Company's AFM24-102 study in advanced EGFR wild-type (EGFRwt) non-small cell lung cancer (NSCLC) will be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) to be held in Chicago on May 31 – June 4, 2024. Patients in the study are treated with the combination of AFM24, Affimed's innate cell engager (ICE®), and atezolizumab, Roche's checkpoint inhibitor (CPI).

Small-Cap Sensations: 3 Stocks Under $10 With 10X Potential
investorplace.com17 May 2024 Sentiment: POSITIVE

Several analysts predict an interest rate decrease is on the horizon for September. This could result in speculative capital shifting away from large-cap stocks.

  • 1(current)
  • 2

What type of business is Affimed NV?

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany.

What sector is Affimed NV in?

Affimed NV is in the Healthcare sector

What industry is Affimed NV in?

Affimed NV is in the Biotechnology industry

What country is Affimed NV from?

Affimed NV is headquartered in Germany

When did Affimed NV go public?

Affimed NV initial public offering (IPO) was on 12 September 2014

What is Affimed NV website?

https://www.affimed.com

Is Affimed NV in the S&P 500?

No, Affimed NV is not included in the S&P 500 index

Is Affimed NV in the NASDAQ 100?

No, Affimed NV is not included in the NASDAQ 100 index

Is Affimed NV in the Dow Jones?

No, Affimed NV is not included in the Dow Jones index

When was Affimed NV the previous earnings report?

No data

When does Affimed NV earnings report?

The next expected earnings date for Affimed NV is 14 November 2024